Patents Assigned to Alba Therapeutics Corporation
  • Patent number: 10723763
    Abstract: The present application provides compositions and methods for treating acute lung injury and acute respiratory distress syndrome. The methods include administering one or more tight junction antagonists to the lung of a subject in need thereof.
    Type: Grant
    Filed: August 12, 2016
    Date of Patent: July 28, 2020
    Assignees: ALBA THERAPEUTICS CORPORATION, UNIVERSITY OF MARYLAND, BALTIMORE
    Inventors: Blake Paterson, Peter Ward, Alessio Fasano
  • Patent number: 10526372
    Abstract: Novel compounds and methods for the inhibition of biological barrier permeability and for the inhibition of peptide translocation across biological barriers are identified. Assays for determining modulators of biological barrier permeability and for peptide translocation across biological barriers are provided. Methods for treating diseases relating to aberrant biological barrier permeability and peptide translocation across biological barriers are provided. Such diseases include celiac disease, necrotizing enterocolitis, diabetes, cancer, inflammatory bowel diseases, asthma, COPD, excessive or undesirable immune response, gluten sensitivity, gluten allergy, food allergy, rheumatoid arthritis, multiple sclerosis, immune-mediated or type 1 diabetes mellitus, systemic lupus erythematosus, psoriasis, scleroderma and autoimmune thyroid diseases.
    Type: Grant
    Filed: January 2, 2018
    Date of Patent: January 7, 2020
    Assignee: ALBA THERAPEUTICS CORPORATION
    Inventors: Sefik Alkan, Amir Tamiz, Kelly Marie Kitchens, Malarvizhi Durai, Neil Poloso, Rosa A. Carrasco
  • Patent number: 9279807
    Abstract: The present invention provides materials and methods for the treatment of celiac disease. In addition, the present invention provides materials and methods of monitoring the treatment of a subject having celiac disease.
    Type: Grant
    Filed: August 22, 2011
    Date of Patent: March 8, 2016
    Assignees: ALBA THERAPEUTICS CORPORATION, UNIVERSITY OF MARYLAND, BALTIMORE
    Inventors: Alessio Fasano, Blake Paterson
  • Patent number: 9265811
    Abstract: Enteric compositions comprising one or more tight junction agonists and/or one or more tight junction antagonists are provided. Compositions of the invention may comprise a delayed-release coating disposed over a tight junction agonist and/or tight junction antagonist layer which may be disposed over an inert core. Delayed-release coatings may be substantially stable in gastric fluid and substantially unstable in intestinal fluid, thus providing for substantial release of the tight junction agonist and/or antagonist from the composition in the duodenum or jejunum of the small intestine.
    Type: Grant
    Filed: February 9, 2007
    Date of Patent: February 23, 2016
    Assignee: ALBA THERAPEUTICS CORPORATION
    Inventors: Blake Paterson, Mark J. Ginski
  • Patent number: 9051349
    Abstract: The invention provides crystalline forms of the peptide Gly-Gly-Val-Leu-Val-Gln-Pro-Gly (SEQ ID NO 1), and salts of the peptide, which may further have associated water molecules. These salts and hydrated salts of the peptide and compositions comprising these materials have advantageous pharmaceutical properties.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: June 9, 2015
    Assignee: Alba Therapeutics Corporation
    Inventors: Roland Callens, Georges Blondeel, Thierry Delplanche
  • Patent number: 8957032
    Abstract: Novel compounds and methods for the inhibition of biological barrier permeability and for the inhibition of peptide translocation across biological barriers are identified. Assays for determining modulators of biological barrier permeability and for peptide translocation across biological barriers are provided. Methods for treating diseases relating to aberrant biological barrier permeability and peptide translocation across biological barriers are provided. Such diseases include celiac disease, necrotizing enterocolitis, diabetes, cancer, inflammatory bowel diseases, asthma, COPD, excessive or undesirable immune response, gluten sensitivity, gluten allergy, food allergy, rheumatoid arthritis, multiple sclerosis, immune-mediated or type 1 diabetes mellitus, systemic lupus erythematosus, psoriasis, scleroderma and autoimmune thyroid diseases.
    Type: Grant
    Filed: May 6, 2009
    Date of Patent: February 17, 2015
    Assignee: Alba Therapeutics Corporation
    Inventors: Sefik Alkan, Amir Tamiz, Kelly Marie Kitchens, Malarvizhi Durai, Neil Poloso, Rosa A. Carrasco
  • Publication number: 20140294894
    Abstract: The present invention provides materials and methods to facilitate the transcutaneous delivery of therapeutic agents. In some embodiments, agonists of tight junctions are used in compositions to facilitate the uptake of therapeutic agents from the skin. In a particular embodiment, the present invention provides immunogenic compositions comprising a tight junction agonist and an antigen. In a particular embodiment, the present invention provides vaccine compositions comprising a tight junction agonist and an antigen.
    Type: Application
    Filed: April 2, 2014
    Publication date: October 2, 2014
    Applicant: Alba Therapeutics Corporation
    Inventors: Dorothea Sesardic, Blake Paterson
  • Patent number: 8796203
    Abstract: The present invention provides materials and methods for the treatment of inflammatory bowel disease (e.g., Crohn's disease and ulcerative colitis). Materials of the invention may include compositions comprising one or more tight junction antagonists and optionally one or more therapeutic agents. Methods of the invention may comprise treating a subject in need thereof with a composition comprising one or more tight junction antagonists and, optionally one or more therapeutic agents.
    Type: Grant
    Filed: September 24, 2012
    Date of Patent: August 5, 2014
    Assignee: Alba Therapeutics Corporation
    Inventors: Blake Paterson, Amir Tamiz, Niranjan Pandey
  • Patent number: 8785374
    Abstract: The present invention provides novel peptides that inhibit and/or reduce the opening of mammalian tight junctions, i.e. peptide tight junction antagonists. The present invention also provides methods for the treatment of excessive or undesirable permeability of a tissue by administering to a subject suffering from such a condition a composition comprising a peptide tight junction antagonist of the invention.
    Type: Grant
    Filed: October 20, 2008
    Date of Patent: July 22, 2014
    Assignee: Alba Therapeutics Corporation
    Inventor: Amir Tamiz
  • Publication number: 20140171377
    Abstract: The present invention provides novel peptides that facilitate the opening of mammalian tight junctions, i.e. tight junction agonists. The present invention also provides methods for the treatment of disease by administering to a subject suffering from the disease a composition comprising a peptide tight junction agonist of the invention in combination with a therapeutically effective amount of an active agent.
    Type: Application
    Filed: September 10, 2013
    Publication date: June 19, 2014
    Applicant: Alba Therapeutics Corporation
    Inventors: Amir Tamiz, Min Li
  • Patent number: 8728491
    Abstract: The present invention provides materials and methods to facilitate the transcutaneous delivery of therapeutic agents. In some embodiments, agonists of tight junctions are used in compositions to facilitate the uptake of therapeutic agents from the skin. In a particular embodiment, the present invention provides immunogenic compositions comprising a tight junction agonist and an antigen. In a particular embodiment, the present invention provides vaccine compositions comprising a tight junction agonist and an antigen.
    Type: Grant
    Filed: May 7, 2008
    Date of Patent: May 20, 2014
    Assignee: Alba Therapeutics Corporation
    Inventors: Dorothea Sesardic, Blake Paterson
  • Publication number: 20130295594
    Abstract: The present invention provides methods and materials, including kits, to evaluate Crohn's disease, including to diagnose, monitor, or determine the efficacy of treatment for Crohn's Disease. The methods involve determining the presence, absence, or level of zonulin in a subject sample. In certain embodiments, the need for more laborious and/or invasive tests to monitor disease state is minimized or obviated.
    Type: Application
    Filed: May 1, 2012
    Publication date: November 7, 2013
    Applicants: Alba Therapeutics Corporation, University of Maryland, Baltimore
    Inventors: Julio Bai, Alessio Fasano, Blake Paterson, Alicia Sambueli
  • Publication number: 20130288950
    Abstract: The present application provides compositions and methods for treating acute lung injury and acute respiratory distress syndrome. The methods include administering one or more tight junction antagonists to the lung of a subject in need thereof.
    Type: Application
    Filed: March 28, 2013
    Publication date: October 31, 2013
    Applicants: ALBA THERAPEUTICS CORPORATION, UNIVERSITY OF MARYLAND, BALTIMORE
    Inventors: Blake Paterson, Peter Ward, Alessio Fasano
  • Patent number: 8557763
    Abstract: The present invention provides novel peptides that facilitate the opening of mammalian tight junctions. i.e. tight junction agonists. Th present invention also provides methods for the treatment of disease by administering to a subject suffereing from the disease a composition comprising a peptide tight junction agonist of the invention in combination with a therapeutically effective amount of an active agent.
    Type: Grant
    Filed: May 18, 2012
    Date of Patent: October 15, 2013
    Assignee: Alba Therapeutics Corporation
    Inventors: Amir Tamiz, Min Li
  • Publication number: 20130122086
    Abstract: Enteric compositions comprising one or more tight junction agonists and/or one or more tight junction antagonists are provided. Compositions of the invention may comprise a delayed-release coating disposed over a tight junction agonist and/or tight junction antagonist layer which may be disposed over an inert core. Delayed-release coatings may be substantially stable in gastric fluid and substantially unstable in intestinal fluid, thus providing for substantial release of the tight junction agonist and/or antagonist from the composition in the duodenum or jejunum of the small intestine.
    Type: Application
    Filed: April 18, 2012
    Publication date: May 16, 2013
    Applicant: Alba Therapeutics Corporation
    Inventors: Blake Paterson, Mark J. Ginski
  • Publication number: 20120322748
    Abstract: The present invention provides novel peptides that facilitate the opening of mammalian tight junctions. i.e. tight junction agonists. The present invention also provides methods for the treatment of disease by administering to a subject suffering from the disease a composition comprising a peptide tight junction agonist of the invention in combination with a therapeutically effective amount of an active agent.
    Type: Application
    Filed: May 18, 2012
    Publication date: December 20, 2012
    Applicant: Alba Therapeutics Corporation
    Inventors: Amir Tamiz, Min Li
  • Patent number: 8198233
    Abstract: The present invention provides novel peptides that facilitate the opening of mammalian tight junctions, i.e. tight junction agonists. The present invention also provides methods for the treatment of disease by administering to a subject suffering from the disease a composition comprising a peptide tight junction agonist of the invention in combination with a therapeutically effective amount of an active agent.
    Type: Grant
    Filed: July 28, 2008
    Date of Patent: June 12, 2012
    Assignee: Alba Therapeutics Corporation
    Inventors: Amir Tamiz, Min Lin
  • Patent number: 8168594
    Abstract: Enteric compositions comprising one or more tight junction agonists and/or one or more tight junction antagonists are provided. Compositions of the invention may comprise a delayed-release coating disposed over a tight junction agonist and/or tight junction antagonist layer which may be disposed over an inert core. Delayed-release coatings may be substantially stable in gastric fluid and substantially unstable in intestinal fluid, thus providing for substantial release of the tight junction agonist and/or antagonist from the composition in the duodenum or jejunum of the small intestine.
    Type: Grant
    Filed: November 11, 2009
    Date of Patent: May 1, 2012
    Assignee: Alba Therapeutics Corporation
    Inventors: Blake Paterson, Mark J. Ginski
  • Publication number: 20120076861
    Abstract: The present invention provides materials and methods for the treatment of celiac disease. In addition, the present invention provides materials and methods of monitoring the treatment of a subject having celiac disease.
    Type: Application
    Filed: August 22, 2011
    Publication date: March 29, 2012
    Applicants: University of Maryland, Baltimore, Alba Therapeutics Corporation
    Inventors: Alessio FASANO, Blake Paterson
  • Patent number: 8034776
    Abstract: The present invention provides materials and methods for the treatment of celiac disease. In addition, the present invention provides materials and methods of monitoring the treatment of a subject having celiac disease.
    Type: Grant
    Filed: October 26, 2007
    Date of Patent: October 11, 2011
    Assignees: Alba Therapeutics Corporation, University of Maryland, Baltimore
    Inventors: Alessio Fasano, Blake Paterson